AMD

The investigators explored the effects of the following covariates on development of AMD: sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension.

Opthea’s lead biologic drug candidate OPT-302, which is under investigation for the treatment of wet AMD, received nonproprietary drug name sozinibercept, which is a critical step in the FDA approval process.

While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.

Researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD.

A recently completed non-human primate study of VGX-0111 demonstrated good tolerability, provided strong transgene expression in the targeted region of the retina, and increased production of the lipids whose decline is associated with macular degeneration.

Over the past decade the progress in retinal disease treatments has exploded with increased numbers of approved pharmaceutical compounds, resulting in more options for treating retinal disease with intravitreal agents and more are in the pipeline.

The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.

The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

Acceptance is based on two phase 3 studies that demonstrated early and sustained vision improvement, meeting primary endpoint of non-inferiority compared to aflibercept.

Efavirenz boosts cholesterol turnover in retina, brain.

A look back on what happened in optometry during the week ofMarch 27-March 31.

Imaging can elucidate visual prognosis and disease progression risk.

A look back on what happened in optometry during the week of March 20-March 24.

Investigators evaluated risuteganib for safety and effectiveness in patients with dry AMD.

These disorders account for most of the vision loss in working-age and elderly Americans.

A look back on what happened in optometry during the week of March 10-March 16.

Research shows how life stressors—such as obesity—reprogram immune system cells and make them destructive to the eye as it ages.

A look back on what's happened in optometry during the week of February 25-March 2.

See the results from our recent poll!

A look back on what's happened in optometry during the week of February 18-February 23.

The eye care community is moving toward a more disruption-resistant system of care, from wearable tech to VEGF-eluting implants.

OPT-302 combined with ranibizumab: covering all the VEGF bases for superior visual gains compared with ranibizumab alone in wet AMD

Vote in our most recent poll!

Advances in drug creation would reduce cost burden of treatment for patients.

See the results from our recent poll!

The trial showed no added benefit of nesvacumab and aflibercept combination therapy over aflibercept monotherapy.

Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.

Kicking off AMD Awareness Month, give us your thoughts!

Benefits include eliminating eyeglass problems and boosting patient confidence.